Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GMPS | P49915 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.56 |
| ▸ | SLC28A1 | O00337 | 2/20 | 0.53 |
| ▸ | PI4KA | P42356 | 2/20 | 0.53 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.53 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.53 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.53 |
| ▸ | DPP4 | P27487 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.53 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.53 |
| ▸ | GAPDH | P04406 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.53 |
| ▸ | STAT6 | P42226 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Psicofuranine SCHEMBL9389898 | 1.00 | GMPS (0.61) | GMPSADORA3ADORA2ASLC28A1PI4KA | |
| Psicofuranine SCHEMBL29441281 | 1.00 | GMPS (0.61) | GMPSADORA3ADORA2ASLC28A1PI4KA | |
| Psicofuranine SCHEMBL691066 | 1.00 | GMPS (0.61) | GMPSADORA3ADORA2ASLC28A1PI4KA | |
| SCHEMBL30716126 | 0.91 | ADORA3 (0.54) | GMPSADORA3ADORA2ASLC28A1PI4KA | |
| SCHEMBL29639535 | 0.91 | ADORA3 (0.54) | GMPSADORA3ADORA2ASLC28A1PI4KA | |
| SCHEMBL3698843 | 0.91 | ADORA3 (0.54) | GMPSADORA3ADORA2ASLC28A1PI4KA | |
| SCHEMBL2270714 | 0.91 | ADORA3 (0.54) | GMPSADORA3ADORA2ASLC28A1PI4KA | |
| SCHEMBL6828797 | 0.90 | ADORA3 (0.53) | GMPSADORA3ADORA2ASLC28A1PI4KA | |
| Psicofuranine SCHEMBL7524270 | 0.89 | ADORA3 (0.74) | ADORA3ADORA2ASLC28A1PI4KAPI4K2B | |
| SCHEMBL2534138 | 0.89 | ADORA3 (0.52) | GMPSADORA3ADORA2ASLC28A1PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| CN-118546849-A | Recombinant engineering strain for heterologously expressing angustmycin and construction method and application thereof | 长沙微智生物科技有限公司 | 2024-08-27 | — | — | CN | claimed |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2024-05-02 | — | — | US | claimed |
| EP-4045504-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | Ai-biopharma (FR) | 2022-08-24 | — | — | EP | claimed |
| CN-113462704-B | Biosynthetic gene cluster of plant cytokinin angustmycin, biological material of biosynthetic gene cluster and application of biosynthetic gene cluster in synthesis of angustmycin | 武汉大学 | 2022-07-05 | — | — | CN | claimed |
| CN-113462704-A | Biosynthetic gene cluster of plant cytokinin angustmycin, biological material of biosynthetic gene cluster and application of biosynthetic gene cluster in synthesis of angustmycin | 武汉大学 | 2021-10-01 | — | — | CN | claimed |
| WO-2021074443-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2021-04-22 | — | — | WO | claimed |
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | LUMINIDE | 2005-04-14 | — | — | US | claimed |
| EP-0098122-B1 | PROCESSES FOR PRODUCING L-PROLINE BY FERMENTATION | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1989-05-31 | — | — | EP | claimed |
| EP-0098122-A2 | Processes for producing L-proline by fermentation | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1984-01-11 | — | — | EP | claimed |
| US-4389483-A | AEROBIC CULTURING A MUTANT OF BREVIBACTERIUM OR COPYNEBACTERIUM | AJINOMOTO COMPANY INCORPORATED (JP) | 1983-06-21 | — | — | US | claimed |
| US-4225585-A | ANGUSTMYCINS | AJINOMOTO COMPANY, INCORPORATED (JP) | 1980-09-30 | — | — | US | claimed |
| JP-57115190-A | — | — | None | — | — | JP | disclosed |
| JP-60024195-A | — | — | None | — | — | JP | disclosed |
| JP-60024195-A | — | — | None | — | — | JP | disclosed |
| JP-53086017-A | — | — | None | — | — | JP | disclosed |
| US-4225585-A | ANGUSTMYCINS | AJINOMOTO COMPANY, INCORPORATED (JP) | 1980-09-30 | — | — | US | disclosed |
| JP-S5386017-A | FUNGICIDES FOR AGRICULTURE AND HORTICULTURE | AJINOMOTO CO INC | 1978-07-29 | — | — | JP | disclosed |
| US-3960660-A | BACILLUS MUTANT REQUIRING ADENINE FOR GROWTH | AJINOMOTO CO., INC. (JA) | 1976-06-01 | — | — | US | disclosed |
| US-3960660-A | BACILLUS MUTANT REQUIRING ADENINE FOR GROWTH | AJINOMOTO CO., INC. (JA) | 1976-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | APEH, PAH, ALAD | GMPS 3600/4885ADORA3 1379/4885ADORA2A 1633/4885 |
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | HAVCR2, NR1H4, NR1H3 | GMPS 4827/4885ADORA3 558/4885ADORA2A 1902/4885 |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | SLC10A1, HAVCR2, HDGF | GMPS 3498/4885ADORA3 3777/4885ADORA2A 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.